~ Buy the KALYDECO (ivacaftor) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR KALYDECO

All Clinical Trials for Kalydeco

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01614457 ↗	Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)	Completed	Cystic Fibrosis Foundation	Phase 3	2012-07-01	The purpose of this study is to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis (CF) who have the R117H-CFTR mutation.
NCT01614457 ↗	Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)	Completed	Cystic Fibrosis Foundation Therapeutics	Phase 3	2012-07-01	The purpose of this study is to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis (CF) who have the R117H-CFTR mutation.
NCT01614457 ↗	Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)	Completed	Vertex Pharmaceuticals Incorporated	Phase 3	2012-07-01	The purpose of this study is to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis (CF) who have the R117H-CFTR mutation.
NCT01614470 ↗	Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation	Completed	Cystic Fibrosis Foundation	Phase 3	2012-07-01	The purpose of this study is to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis (CF) who have a non-G551D cystic fibrosis transmembrane regulator (CFTR) gating mutation (any one of the following CFTR mutations: G178R, G551S, S549N, S549R, G970R, G1244E, S1251N, S1255P, or G1349D).
NCT01614470 ↗	Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation	Completed	Cystic Fibrosis Foundation Therapeutics	Phase 3	2012-07-01	The purpose of this study is to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis (CF) who have a non-G551D cystic fibrosis transmembrane regulator (CFTR) gating mutation (any one of the following CFTR mutations: G178R, G551S, S549N, S549R, G970R, G1244E, S1251N, S1255P, or G1349D).

Clinical Trial Conditions for Kalydeco

Condition Name

Condition Name for Kalydeco
Intervention	Trials
Cystic Fibrosis	19
Chronic Obstructive Pulmonary Disease	3
Chronic Bronchitis	2
Healthy	2

Condition MeSH

Condition MeSH for Kalydeco
Intervention	Trials
Cystic Fibrosis	19
Fibrosis	17
Pulmonary Disease, Chronic Obstructive	3
Lung Diseases, Obstructive	3

Clinical Trial Locations for Kalydeco

Trials by Country

Trials by Country for Kalydeco
Location	Trials
United States	162
United Kingdom	10
Canada	8
Australia	7
Belgium	4

Trials by US State

Trials by US State for Kalydeco
Location	Trials
Alabama	11
Massachusetts	9
California	9
Pennsylvania	8
Missouri	8

Clinical Trial Progress for Kalydeco

Clinical Trial Phase

Clinical Trial Phase for Kalydeco
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	6
Phase 2	6

Clinical Trial Status

Clinical Trial Status for Kalydeco
Clinical Trial Phase	Trials
Completed	16
Recruiting	6
Active, not recruiting	1

Clinical Trial Sponsors for Kalydeco

Sponsor Name

Sponsor Name for Kalydeco
Sponsor	Trials
Vertex Pharmaceuticals Incorporated	13
University of Alabama at Birmingham	6
Cystic Fibrosis Foundation	5

Sponsor Type

Sponsor Type for Kalydeco
Sponsor	Trials
Other	22
Industry	19
NIH	3